China News Service, September 17 (Reuters)-According to a report from Reuters on the 17th, in the Phase III clinical trial of the new crown vaccine jointly developed by the University of Oxford and the British pharmaceutical company AstraZeneca, a British volunteer had an adverse reaction and the trial was temporarily suspended. .
According to a document summarizing information about volunteers published online by the University of Oxford, the volunteers had adverse reactions that were not related to the vaccine itself.
On September 8, the vaccine named AZD1222 was in the third phase of human testing. Due to a "serious adverse reaction" from a British volunteer, the vaccination test was temporarily suspended for an independent committee to review the safety data.
The volunteer reportedly developed neurological symptoms related to a rare myelitis.
According to documents disclosed by the University of Oxford, "After independent review, these diseases are considered unlikely to be related to vaccines, or there is insufficient evidence to determine that these diseases are related to vaccines."
AstraZeneca and Oxford University have not yet commented on the news.
AstraZeneca announced on the 12th that this vaccine has been approved by the British safety regulatory agency to resume clinical trials.
At present, clinical trials of this vaccine in the United Kingdom, Brazil and South Africa have resumed, but trials in the United States are still suspended.